Connect with us

Business

MAN seeks Nigeria’s exclusivity on Oxytocin injection

Published

on

 

Nigeria will move for the exclusivity of Oxytocin injection production in Africa, in order to protect the country’s local market and also the manufacturing sector, the Manufacturers Association of Nigeria (MAN) has said.

The Director-General, MAN, Segun Ajayi-Kadir, made this known at the formal unveiling of Oxytocin and Magnesium Sulphate injection in Lagos recently.

 

According to him, the association will parley with the United States Pharmacopeia (USP), United States Agency for International Development (USAID) and the Nigerian manufacturer, Juhel Nigeria Limited, to ensure that Nigeria gets the exclusive right.

Ajayi-Kadir noted that Oxytocin injection, which is the first of its kind in Africa, would be adequately protected in Nigeria, since the country now has the capacity to produce it in abundance with the support of the USP and USAID.

He said that the government wanted to enhance the capacity of the country’s manufacturing sector to compete effectively with others in the continent and henceforth, some Nigerian products would continue to enjoy exclusive right in the continent.
“MAN is going to move for the exclusivity of Oxytocin injection manufacturing in Nigeria, in order to protect our local market,” he said.

 

“We are going to meet with the tripartite firms involved in the production of Oxytocin injection -United States Pharmacopeia (USP), United States Agency for International Development (USAID) and Juhel Nigeria Limited – on getting the exclusive right for Nigeria in the manufacturing of the product locally, since we now have the capacity to produce locally and export.

 

“With the Oxytocin injection exclusive right, we want to further get our name out of the rock bottom ranking on the World Bank’s ease of doing business among the comity of nations. So we want to tackle dumping of product in Nigeria.”

Also speaking at the event, the Chief Executive Officer, Juhel Nigeria Limited, Dr. Ifeanyi Okoye, stated that within the last decade, Nigeria occupied the unenviable position of the fourth highest maternal death rate in the world, accounting for 19 per cent of 830 global maternal deaths.

 

He explained that post-partum haemorrhage (PPH) or excessive bleeding after child birth is one of the major complications of births, and it accounts for 20-30 per cent of all maternal death.

He, however, pointed out that PPH is both treatable and preventable using, according to WHO recommended guidelines, Oxytocin injection as a frontline drug of choice.

Speaking further, he said that Oxytocin injection was a safe and potent drug, which has been in existence in the Nigerian pharmaceutical market for years.

“This development raised a pertinent question of why? A survey conducted in 2016 by USP Convention/Promoting the Quality of Medicine (PQM) project, supported by USAID in conjunction with National Agency for Food and Drug Administration and Control (NAFDAC) sought to answer this, by determining the quality of Oxytocin injections in hospitals and clinics across six geopolitical zones in Nigeria.

“The result indicated that 74.2 per cent of Oxytocin in circulation failed quality laboratory evaluation. In other words, three out of four imported brands are sub-standard,” he said.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Categories

Pages

Close

Trending

%d bloggers like this: